Bob Lang

Bob Lang has been a private trader in equity and option markets for several years and manages separate accounts via Aztec Capital LLC. He has managed a $300 million pension and 401(k) plan for a Southern California cooperative. In early 2000, Lang started a hedge fund for private and institutional clients. This fund, Aztec Partners, was a top-performing fund that year relative to its peer group. In 2002, Lang worked with floor traders in the active bond-trading group of Countrywide Capital Markets. In May 2011, Lang launched an options trading service called Explosive Options.

Recent Articles By The Author

Latest Results From This Retail Name Show the Power of Its Strategy

TJX Cos. topped expectations for the April quarter on strong same-store sales.

This Portfolio Name Takes a Pit Stop Before Next Move Up

Ross Stores' pullback is ideal for adding more shares.

What the Huawei Situation Means for the Portfolio

How we see the fallout affecting Apple, Universal Display and Alphabet.

Review Your Risk Management Principles to Stay on Track

Review Your Risk Management Principles to Stay on Track

It is good practice to give our tactics a periodic look in order to refine them in a changing market environment.

Chart of the Day: Tesla

Tesla's chart shows the stock is driving off the road.

Trifecta Stocks Weekly Roundup

With the market trading lower under the weight of trade uncertainty, the portfolio enjoyed a week in which the majority of our holdings moved higher.

Pyxus International Is Burning Out, Plus 4 Other Stocks That Look Good Short

PYX, MOS, IRM, RL and MUR all recently were downgraded by TheStreet's Quant Ratings.

Trade Drama, Retail Sales and Streaming Video Update

We have positions in three companies newly vying for a share in the streaming video market -- Apple, AT&T and Disney.

A Powerful Day for This Position: Can We Get Follow Through?

Alphabet's good turnover and sharp bounce off a low relative strength level Wednesday was impressive.

Chart of the Day: Arena Pharmaceuticals

Biotech stock Arena is flexing its muscles.